Home / Incyte CORP (INCY) / tafasitamab
Forward catalyst · INCY

tafasitamab

Sponsor Incyte CORP · listed as INCY

READOUT Phase 3 Confidence: medium Source: clinicaltrials

Next catalyst

Event typeREADOUT
Expected date2026-09-01
As disclosedSep 1, 2026
Date precisionday
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT04824092
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorIncyte Corporation
Listed asINCY
Condition(s)Diffuse Large B-cell Lymphoma
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 →   More INCY catalysts